McKesson reports Q2 EPS 8.92, consensus $9.05

Reports Q2 revenue $103.15B, consensus $104.12B. “McKesson’s (MCK) second quarter results underscore the strength of our differentiated assets, capabilities, and continued momentum as a diversified healthcare services leader. We delivered record revenue in the quarter of $103 billion, increasing 10% and Adjusted Earnings per Diluted Share accelerating 39% compared to the prior year. These results reflect disciplined execution of our enterprise strategy – advancing growth in oncology and multispecialty and biopharma services. We remain confident in our ability to create value for our customers, partners, employees, and shareholders,” said Brian Tyler, CEO.